Peritoneal Carcinomatosis of Rare Ovarian Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Multi-Institutional Cohort from PSOGI and BIG-RENAPE.

Date publication

juin 2018

Journal

Annals of surgical oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr HEYD Bruno

Tous les auteurs :
Mercier F, Bakrin N, Bartlett DL, Goere D, Quenet F, Dumont F, Heyd B, Abboud K, Marolho C, Villeneuve L, Glehen O, ,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29637438

Résumé

Ovarian cancer is the most common deadly cancer of gynecologic origin. Patients often are diagnosed at advanced stage with peritoneal metastasis. There are many rare histologies of ovarian cancer; some have outcomes worse than serous ovarian cancer. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) can be considered for patients with recurrence. This study was designed to assess the impact of CRS and HIPEC on survival of patient with peritoneal metastasis from rare ovarian malignancy.

Mots clés

Adolescent, Adult, Aged, Aged, 80 and over, Carcinoma, Endometrioid, secondary, Cytoreduction Surgical Procedures, adverse effects, Disease-Free Survival, Female, Follow-Up Studies, Granulosa Cell Tumor, secondary, Humans, Hyperthermia, Induced, Lymphatic Metastasis, Middle Aged, Neoplasms, Cystic, Mucinous, and Serous, secondary, Neoplasms, Germ Cell and Embryonal, secondary, Ovarian Neoplasms, pathology, Peritoneal Neoplasms, secondary, Rare Diseases, pathology, Retrospective Studies, Survival Rate, Teratoma, secondary, Treatment Outcome, Young Adult

Référence

Ann. Surg. Oncol.. 2018 Jun;25(6):1668-1675